STOCK TITAN

PROVECTUS BIOPHARMACEUTICALS (PVCT) SEC Filings, Feb-Apr 2026

PVCT OTC
Rhea-AI Summary

Provectus Biopharmaceuticals, Inc. is soliciting proxies for its 2026 Annual Meeting to be held on June 18, 2026 where stockholders will vote on five proposals: election of four directors; an advisory vote on executive compensation; ratification of CBIZ as auditor; and two linked charter amendments to permit a reverse stock split (1-for-10 to 1-for-50) and a corresponding decrease in authorized shares if the split is implemented.

The proxy discloses governance, compensation and related-party financing details: 420,279,879 shares of common stock outstanding as of April 20, 2026, significant outstanding option awards (total 53,878,349 options exercisable at $0.29), a 2024 equity plan authorizing 100,000,000 shares, and related-party convertible note financings led by certain directors and a 5% stockholder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
proxy
-
Rhea-AI Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported two non-market, derivative exercises. An 8% unsecured convertible promissory note, issued under the company’s 2025 financing, was converted into 33,977 shares of Series D-1 Convertible Preferred Stock at $2.862 per share. Each Series D-1 share is convertible into 10 common shares, and on the same date these preferred shares were converted into 339,770 shares of common stock. Following the conversion, Pershing directly owned 2,744,031 shares of common stock. The Series D-1 preferred would otherwise automatically convert into common stock on December 31, 2028, unless converted earlier under its terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.89%
Tags
insider
-
Rhea-AI Summary

Provectus Biopharmaceuticals CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note that can be converted into 17,471 shares of Series D-1 Convertible Preferred Stock. The note may be voluntarily converted into Series D-1 Preferred at a price of $2.862 per share at any time while outstanding.

According to the disclosure, any outstanding principal and interest on the note will automatically convert into Series D-1 Preferred at the same $2.862 price per share twelve months after the note’s issue date. Each Series D-1 Preferred share is itself convertible into 10 shares of common stock and will automatically convert to common stock on December 31, 2028, unless converted earlier under its terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.86%
Tags
insider
Rhea-AI Summary

Provectus Biopharmaceuticals, Inc. files its 2025 annual report outlining a broad rose bengal sodium (RBS)–based immunotherapy platform, spanning oncology, dermatology, ophthalmology and multiple early non-clinical programs. The company highlights an extensive U.S. and international patent estate supporting its pharmaceutical-grade RBS and PV‑10/PH‑10 candidates.

The report warns of substantial doubt about the company’s ability to continue as a going concern, citing an accumulated net loss of approximately $263 million since inception, a cash balance of $251,291 and a working capital deficit of $6,329,503 as of December 31, 2025. Management states that additional capital will be required in 2026 and beyond to advance clinical trials and operations.

As of June 30, 2025, the aggregate market value of common equity held by non‑affiliates was $30,585,685, based on a price of $0.075 per share. There were 420,279,879 shares of common stock outstanding as of March 23, 2026. The company also discloses cybersecurity, environmental and human‑capital practices, including a six‑person full‑time workforce and use of cloud‑based, third‑party monitored IT systems.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.86%
Tags
annual report
-
Rhea-AI Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported non‑market transactions converting debt and preferred equity into common stock. An 8% unsecured convertible promissory note converted into 49,067 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share. Those 49,067 Series D-1 shares were then converted into 490,670 shares of common stock, reflecting the 10:1 conversion ratio. Following these conversions, Pershing directly holds 2,710,054 shares of common stock. The Series D-1 Preferred Stock is also described as automatically converting into common stock on December 31, 2028 unless converted earlier under its terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
insider
-
Rhea-AI Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note. The note allows him to convert outstanding principal and interest into shares of Series D-1 Convertible Preferred Stock at $2.862 per share, with automatic conversion into Series D-1 Preferred twelve months after the issue date. Each Series D-1 Preferred share is convertible into 10 shares of common stock, and the preferred stock will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
insider
Rhea-AI Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported acquiring an 8% unsecured convertible promissory note as a derivative security. The note was issued under the company’s 2025 Financing and does not immediately involve common shares, but it can later convert into equity.

The footnotes state that the outstanding principal and interest of the note may be converted into shares of Series D-1 Convertible Preferred Stock at a price per share of $2.862, either voluntarily at any time or automatically twelve months after the issue date. Each Series D-1 Preferred share is in turn convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
insider
-
Rhea-AI Summary

PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing reported the grant of an 8% unsecured convertible promissory note. The note may be voluntarily converted into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share while it is outstanding.

The outstanding principal and interest will automatically convert into Series D-1 Preferred Stock at $2.862 per share twelve months after the note’s issue date. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock, and the preferred stock will automatically convert into common stock on December 31, 2028 unless converted earlier.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
insider
-
Rhea-AI Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported a non-cash conversion of an 8% unsecured convertible promissory note into 47,180 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share on February 20, 2026.

Each Series D-1 Preferred share is convertible into 10 common shares and will automatically convert into common stock on December 31, 2028, unless converted earlier under its certificate of designation. Following this transaction, Pershing directly owned 2,660,987 Series D-1 Preferred shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
insider
Rhea-AI Summary

Provectus Biopharmaceuticals CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note. This derivative security allows him to convert the note’s outstanding principal and interest into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share at any time while the note is outstanding.

The footnotes state that, twelve months after the note’s issue date, the outstanding principal and interest will automatically convert into Series D-1 Preferred Stock at the same $2.862 conversion price. Each Series D-1 Preferred share is then convertible into 10 shares of Provectus common stock and will automatically convert into common stock on December 31, 2028, unless converted earlier under its terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
insider

FAQ

How many PROVECTUS BIOPHARMACEUTICALS (PVCT) SEC filings are available on StockTitan?

StockTitan tracks 65 SEC filings for PROVECTUS BIOPHARMACEUTICALS (PVCT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for PROVECTUS BIOPHARMACEUTICALS (PVCT)?

The most recent SEC filing for PROVECTUS BIOPHARMACEUTICALS (PVCT) was filed on November 16, 2026.